Respiri Limited (ASX:RSH)

5.2¢

right-arrow Created with Sketch. 0.002 (4%)
MCAP $36.14M
Last trade 10.32am 28/01/2022 20mins delayed

Latest Announcements

08.25am 28/01/2022 Price SensitivePSRSHRespiri Limited
23/12/2021 Price SensitivePSRSHRespiri Limited
25/11/2021RSHRespiri Limited
22/11/2021RSHRespiri Limited
15/11/2021RSHRespiri Limited
258
MCap
15/11/2021RSHRespiri Limited
26/10/2021 Price SensitivePSRSHRespiri Limited
14/10/2021RSHRespiri Limited

Company Overview

Respiri Limited is an Australia-based company, engaged in research, development and commercialization of medical devices, and the development of mobile health applications. The Company's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The Company has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.

RSH in the news

Respiri (RSH) signs a five-year non-exclusive distribution and marketing deal with US-based…
Respiri (RSH) begins selling its wheezo device across more than 570 pharmacies…
Respiri (RSH) has signed an agreement with TerryWhite Chemmart to sell and…
Respiri (RSH) has received United States Food and Drug Administration (FDA) clearance…

Search Previous Announcements